Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus

Statistics in Medicine

Volumn 32, Issue 11, 2013, Pages 1917-1953

  Korostil, Igor A ^a   Peters, Gareth W ^b   Cornebise, Julien ^c   Regan, David G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adaptive Markov chain Monte Carlo; Calibration; Forward projection; Genital warts; Human papillomavirus (HPV); Sexual mixing matrix

Indexed keywords

ADAPTIVE MARKOV CHAIN MONTE CARLO ALGORITHM; ADULT; AGE; ALGORITHM; ARTICLE; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; EPIDEMIC; FEMALE; FORWARD PROJECTION ALGORITHM; GENDER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NONLINEAR SYSTEM; SAMPLING; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; WART VIRUS;

AUSTRALIA; BAYES THEOREM; DATA INTERPRETATION, STATISTICAL; EPIDEMICS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MODELS, STATISTICAL; MONTE CARLO METHOD; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84877142836     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5590     Document Type: Article

References (72)

1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3):S1-S10.
2. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12(5-6):291-307.
3. Burchell AN, Winer RL, de Sanjose S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24(Suppl 3):S52-S61.
4. Lacey CJ, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S35-S41.
5. Pomfret TC, Gagnon JM, Jr, Gilchrist AT. Quadrivalent human papillomavirus (hpv) vaccine: a review of safety, efficacy, and pharmacoeconomics. Journal of Clinical Pharmacy and Therapeutics 2011; 36(1):1-9.
6. Stanley M. Prophylactic human papillomavirus vaccines: will they do their job? Journal of Internal Medicine 2010; 267(3):251-259.
7. Garland SM, Brotherton JM, Fairley CK, Gertig DM, Saville M. Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia's role. Sexual Health 2010; 7(3):227-229.
8. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press: Oxford, 1992.
9. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. Journal of Infectious Diseases 2005; 191(Suppl 1):S97-S106.
10. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Medical Decision Making 2003; 23(1):76-82.
11. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Statistics in Medicine 1999; 18(23):3263-3282.
12. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine 2006; 3:624-632.
13. Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010; 28(24):4091-4102.
14. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bulletin of Mathematical Biology 2008; 70:2126-2176.
15. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13(6):631-639.
16. Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sexual Health 2007; 4:147-163.
17. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sexual Health 2010; 7(3):352-358.
18. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769. DOI: 10.1136/bmj.a769.
19. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine 2008; 359(8):821-832.
20. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical screening program. Sexual Health 2007; 4:165-175.
21. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27(2):127-147.
22. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerging Infectious Diseases 2003; 9(1):37-48.
23. Keeling M, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton University Press: Princeton, NJ, 2007.
24. Vynnycky E, White RG. An Introduction to Infectious Disease Modelling. Princeton University Press: Princeton, NJ, 2010.
25. Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlee F, Franco EL. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. American Journal of Epidemiology 2006; 163(6):534-543.
26. Vande Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. American Journal of Epidemiology 2007; 165(7):762-775.
27. Kjær SK, Trung Nam T, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw KL, Nygård J, Nygård M. The burden of genital warts: a study of nearly 70, 000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases 2007; 196(10):1447-1454. DOI: 10.1086/522863. URL http://dx.doi.org/10.1086/522863.
28. Grulich AE, deVisser RO, Smith AMA, Rissel CE, Richters J. Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults. Australian and New Zealand Journal of Public Health 2003; 27(2):230-233.
29. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. International Journal of STD & AIDS 1998; 9(10):571-578.
30. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S. Genital warts incidence and health care resource utilisation in Australia. Sexually Transmitted Infections 2009; 86:181-186.
31. Newall AT, Brotherton JML, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, Esser MT, Erick J, Bryan J, Formica N, MacIntyre CR. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clinical Infectious Diseases 2008; 46:1647-1655.
32. Regan DG, Philp DJ, Waters EK. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sexual Health 2010; 7:368-375.
33. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, vande Wijgert JH. Factors affecting transmission of mucosal human papillomavirus. Lancet Infectious Diseases 2010; 10(12):862-874.
34. Saltelli A, Tarantola S, Campolongo F. Sensitivity analysis as an ingredient of modeling. Statistical Science 2000; 15(4):377-395.
35. Hoare A, Regan DG, Wilson DP. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theoretical Biology and Medical Modelling 2008; 5:1-18.
36. Gilks W, Richardson S, Spiegelhalter D. Markov Chain Monte Carlo in Practice. Chapman & Hall/CRC: Boca Raton, FL, 1996.
37. Brooks S. Markov chain Monte Carlo method and its application. Journal of the Royal Statistical Society: Series D (The Statistician) 1998; 47(1):69-100.
38. Andrieu C, Thoms J. A tutorial on adaptive MCMC. Statistics and Computing 2008; 18(4):343-373.
39. Chib S, Greenberg E. Understanding the Metropolis-Hastings algorithm. American Statistician 1995; 49(4):327-335.
40. Roberts G, Rosenthal J. Optimal scaling for various Metropolis-Hastings algorithms. Statistical Science 2001; 16(4):351-367.
41. Atchadé Y, Rosenthal J. On adaptive Markov chain Monte Carlo algorithms. Bernoulli 2005; 11(5):815-828.
42. Andrieu C, Atchade YF. On the efficiency of adaptive MCMC algorithms. Proceedings of the 1st International Conference on Performance Evaluation Methodolgies and Tools, ACM New York, NY, 2006; 43.
43. Haario H, Saksman E, Tamminen J. An adaptive Metropolis algorithm. Bernoulli 2001; 7:223-242.
44. Roberts GO, Rosenthal JS. Examples of adaptive MCMC. Journal of Computational and Graphical Statistics 2009; 18:349-367.
45. Trottier H, Philippe P. Deterministic modeling of infectious diseases: theory and methods. The Internet Journal of Infectious Diseases 2001; 1(2):3.
46. Trottier H, Philippe P. Deterministic modeling of infectious diseases: applications to measles and other similar infections. The Internet Journal of Infectious Diseases 2002; 2(1). DOI: 10.5580/89b.
47. Bartlett M. Measles periodicity and community size. Journal of the Royal Statistical Society. Series A (General) 1957; 120(1):48-70.
48. Brauer F, Castillo-Chavez C. Mathematical models in population biology and epidemiology, 2001.
49. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, Abrahamsen M, Harris RB. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. The Journal of Infectious Diseases 2008; 198:827-835.
50. Smith AMA, Rissel CE, Richters J, Grulich AE, deVisser RO. Sex in Australia: the rationale and methods of the Australian study of health and relationships. Australian and New Zealand Journal of Public Health 2003; 27:106-117. DOI: 10.1111/j.1467-842X.2003.tb00797.x.
51. Trottier H, Mahmud S, Carlos M Prado J, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. The Journal of Infectious Diseases 2008; 197:1436-1447.
52. Rissel CE, Richters J, Grulich AE, deVisser RO, Smith AMA. Sex in Australia: selected characteristics of regular sexual relationships. Australian and New Zealand Journal of Public Health 2003; 27(2):124-130.
53. Boyle FM, Dunne MP, Purdie DM, Najman JM, Cook MD. Early patterns of sexual activity: age cohort differences in Australia. International Journal of STD & AIDS 2003; 14(11):745-752. DOI: 10.1258/09564620360719787. URL http://dx.doi.org/10.1258/09564620360719787.
54. Pitts MK, Couch MA, Smith AMA. Men who have sex with men (MSM): how much to assume and what to ask? Medical Journal of Australia 2006; 185(8):450-452.
55. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IMA Journal of Mathematics Applied in Medicine & Biology 1994; 11:161-192.
56. Ghani AC, Swinton J, Garnett GP. The role of sexual partnership networks in the epidemiology of gonorrhea. Sexually Transmitted Diseases 1997; 24(1):45-56.
57. Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philosophical Transactions of the Royal Society B: Biological Sciences 1993; 342:137-159.
58. Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behavior: insights from mathematical models. Journal of Infectious Diseases 1996; 174:S150-S161.
59. Garnett GP, Hughes JP, Anderson RM, Stoner BP, Aral SO, Whittington WL, Handsfield HH, Holmes KK. Sexual mixing patterns of patients attending sexually transmitted diseases clinics. Sexually Transmitted Diseases 1996; 23(3):248-257.
60. Ghani A, Garnett G. Measuring sexual partner networks for transmission of sexually transmitted diseases. Journal of the Royal Statistical Society: Series A (Statistics in Society) 1998; 161:227-238. DOI: 10.1111/1467-985X.00101.
61. Kim J, Andres-Beck B, Goldie S. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer 2007; 97:1322-1328.
62. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases 2007; 13(1):28-41.
63. Ditlevsen S, DeGaetano A. Mixed effects in stochastic differential equation models. REVSTAT-Statistical Journal 2005; 3(2):137-153.
64. Ditlevsen S, DeGaetano A. Stochastic vs. deterministic uptake of dodecanedioic acid by isolated rat livers. Bulletin of Mathematical Biology 2005; 67(3):547-561.
65. Hairer E, Wanner G. Solving Ordinary Differential Equations II. Stiff and Differential-Algebraic Problems, Second Revised, Springer Series in Computational Mathematics, Vol.14. Springer, 1996.
66. Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, OReilly SF, Koutsky LA. Development of genital warts after incident detection of human papillomavirus infection in young men. The Journal of Infectious Diseases 2010; 202:1181-1184.
67. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA. Development and duration of human papillomavirus lesions, after initial infection. The Journal of Infectious Diseases 2005; 191:731-738.
68. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clinical Infectious Diseases 2003; 36:1397-1403.
69. Roberts GO, Rosenthal GS. Optimal scaling for various Metropolis-Hastings algorithms. Statistical Science 2001; 16(4):351-367.
70. Atchadé Y, Fort G, Moulines E, Priouret P. Adaptive Markov chain Monte Carlo: theory and methods, 2009.
71. Blower S, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. International Statistical Review/Revue Internationale de Statistique 1994; 62(2):229-243.
72. Garnett GP, Anderson RM. Contact tracing and the estimation of sexual mixing patterns: the epidemiology of gonococcal infections. Sexually Transmitted Diseases 1993; 4:181-191.